In relapsed/refractory AML, the PD-1 blocking antibodies pembrolizumab and nivolumab in combination with the HMA azacitidine induced response rates of approximately 30% that were of short duration [24]. The gene discussed is PDCD1; the disease is acute myeloid leukemia.